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PTEN Methylation Dependent Sinonasal Mucosal Melanoma
Case Report
Sinonasal mucosal melanoma (SMM) is an aggressive and rare type of melanoma.
Although the classic RAS-RAF-MEK pathway is thought to be the main pathway 
involved in melanoma pathogenesis, genetic alterations in the phosphatidylinositol
3-kinase–AKT pathway, including PTEN-regulated signaling, are also thought to con-
tribute. So far, data regarding altered PTEN expression and epigenetic mechanism of
PTEN silencing in development of SMM is extremely limited. Herein we report on a
case of SMM with liver and bone metastases with an epigenetic alteration of PTEN.
Results of mutation analysis for BRAF, NRAS, HRAS, KRAS, PIK3CA, c-Kit, and PTEN
were negative; however, methylation of PTEN CpG islands was observed. Our case
not only supports PTEN as a major tumor suppressor involved in melanoma tumori-
genesis, but also a potential epigenetic mechanism of PTEN silencing in development
of SMM.
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Introduction
Sinonasal mucosal melanoma (SMM) is an extremely rare
tumor, accounting for less than 1% of all western melanomas
[1]. The general incidence of SMM in Asia is poorly under-
stood and under-represented in the English literature. It is a
mucosal melanocytic neoplasm characterized by a high ten-
dency to recur and metastasize to various distant sites. The
molecular-driven stepwise transformation of melanocytes
has been extensively documented in melanoma, however,
much less is known about the rarer and more aggressive
forms of primary mucosal melanoma, including SMM. 
Aberrant activation of the mitogen-activated protein 
kinase (MAPK) pathway has been reported in 70% of mela-
noma, and it has been considered that the MAPK pathway
is the major signaling pathway involved in melanoma patho-
genesis. Mutations in proteins along the RAS-RAF-MEK
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pathway have been well documented in melanoma, with 
diverse variations according to its subtypes (63% BRAF, 26%
NRAS, and 3% KIT in overall) [2]. Recently, therapies target-
ing mutations of the MAPK pathway have brought signifi-
cant survival improvement, particularly with the BRAF
inhibitor targeting V600E BRAFmutation [3]. However, there
are still a significant number of patients without mutations
of the MAPK pathway, in whom treatment can be extremely
challenging. Greater clarification of additional or unknown
genetic alterations in other signaling pathways is needed, as
they may be exploited as new therapeutic targets.
In addition to the MAPK pathway, the phosphatidylinos-
itol 3-kinase (PI3K)–AKT pathway is also considered to have
a critical role in the pathogenesis of melanoma. Deletion or
mutation of phosphatase and tensin homologue (PTEN), a
tumor suppressor gene at 10q23.3, has been reported in a 
variety of advanced tumors including malignant melanoma.
The PTEN gene encodes a phosphatase that degrades the
product of PI3K [4]. Hence the loss of function of PTEN from
tumor cells causes accumulation of critical messenger lipids,
which in turn increase AKT phosphorylation and activity,
leading to decreased apoptosis and increased mitogen sig-
naling. Because PTEN protein is low to absent in a significant
number of melan-omas whereas mutations and deletions of
PTEN gene vary widely from 10% to 60% [4], speculation that
PTEN inactivation might occur through a mechanism other
than mutation, such as epigenetic silencing, has emerged.
Aberrant CpG island methylation of PTEN has been identi-
fied as an alternative mechanism of PTEN inactivation in var-
ious type of cancers including lung cancer, endometrial
carcinoma, prostate cancer, brain tumors, cervical neoplasm,
malignant melanoma, hematologic malignancies and 
nasopharyngeal carcinoma [5]. Due to the low incidence of
SMM, study of the molecular abnormalities relevant to the
biology of this melanoma subtype has been limited [6,7]. In
particular the mechanisms of PTEN silencing are little under-
stood. In fact, epigenetic silencing of PTEN in sinonasal type
of melanoma has not been reported previously. Herein we
report on a case of SMM in a 53-year-old woman which
showed reduced PTEN expression with methylation of the
PTEN promoter, suggesting that epigenetic PTEN silencing
is one of the possible mechanisms involved in SMM devel-
opment.
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Fig. 1. Imaging analysis of the patient. (A) Magnetic resonance imaging (MRI) of the paranasal sinuses shows an enhancing
soft tissue lesion in the left frontoethmoid sinus extending to the left orbit. (B, C) Multiple metastases are seen in liver and
vertebrae in the abdominopelvic computed tomography and spine MRI scan.
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Case Report
A 53-year-old woman presented with complaints of a left
orbit mass with orbital swelling. The patient had symptoms
of diplopia and intermittent headache for 2 months. There
was no relevant past medical or family history. Magnetic 
resonance imaging (MRI) scan of the sinuses showed an 
enhancing soft tissue lesion in the left frontoethmoid sinus
extending to the left orbit and anterior cranial fossa (Fig. 1A)
with another enhancing lesion observed at the left sphenoid
ridge. Nasopharyngeal biopsy of the mass showed round
tumor cells with atypia, showing pleomorphic and hyper-
chromatic nuclei with prominent nucleoli (Fig. 2A). In 
immunohistochemical staining, tumor cells were positive for
S-100, Melan A, human melanoma black 45, Fli-1, and CD99
resulting in the diagnosis of malignant mucosal melanoma
(Fig. 2B and C). 
Further imaging evaluation with abdominopelvic com-
puted tomography (CT) and spine MRI revealed multiple 
hepatic and bone metastases (Fig. 1B and C). MRI of the spine
showed bony metastases in the C2, C7, and T10 vertebrae,
and abdominopelvic CT showed innumerable metastatic
nodules in the both lobes of the liver.
For genetic analysis, genomic DNA was extracted from a
formalin-fixed, paraffin-embedded tissue block using the 
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany).
Pyrosequencing was performed using a PyroMark Q24 
(Qiagen, Germantown, MD); mutations for BRAF, NRAS,
HRAS, KRAS, PIK3CA, GNAQ, GNA11, and EGFR were not
found [8]. KIT copy number was also assessed using a Quan-
tiTect SYBR Green PCR Kit (Qiagen) and calculated accord-
ing to a previously described method [9], which revealed
lack of KIT amplification. Agarose gel electrophoresis of
PTEN PCR products following the previously described
method [10] showed a band of PTEN product in the patient
sample compared to control cell line SK-MEL-24 with PTEN
deletion, demonstrating the absence of PTEN deletion (Fig.
3A). The methylation status of the PTEN promoter region
was additionally examined by pyrosequencing using bisul-
fite-modified DNA, which revealed methylations of five
PTEN CpG island sites (Fig. 3B). Subsequent immunohisto-
chemical staining of PTEN protein (rabbit polyclonal anti-
body, Invitrogen, Carlsbad, CA) in the biopsy specimen
showed decreased expression of PTEN in the tumor cells
(Fig. 2D). Finally, the patient was diagnosed as SMM with
Fig. 2.  Pathologic findings of the biopsy specimen obtained from the nasal cavity mass. (A) Round tumor cells with atypia,
showing pleomorphic and hyperchromatic nuclei with prominent nucleoli are seen (H&E staining, !400). (B-D) Immuno-
histochemistry staining shows positive staining in the tumor cells for S-100 (B) and Melan A (C) (B and C, !200), and 
decreased level of PTEN protein expression (D, !200).
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multiple liver and bone metastases, with an epigenetic alter-
ation of PTEN promoter. 
As the patient was not considered amenable for surgical
excision due to the presence of distant metastases, she was
treated with palliative chemotherapy with dacarbazine. MRI
imaging after the fourth cycle showed partial response to
systemic treatment, showing decrease in the size of the 
primary orbital lesion and multiple metastatic sites. However
after the sixth cycle, the patient showed rapid progression of
the disease with leptomeningeal seeding and increased size
and number of liver and bone metastases. The patient even-
tually expired of progressive disease 6 months after the 
initial diagnosis.
Discussion
SMM is a rare type of malignant melanoma, accounting for
less than 1% of all western melanomas and less than 5% of
all sinonasal tract neoplasms [1]. Although SMM accounts
for only a small fraction of melanoma, the incidence contin-
ues to increase by 6% to 7% every year [11]. Symptoms at
presentation are not specific and the diagnostic latency can
be long [12]. Although only a few data are available regard-
ing the genetic alterations in SMM, molecular studies 
reported so far have demonstrated that these tumors only
rarely harbor BRAF mutation [6,7]. Prognosis remains poor,
unlike other subtypes of melanoma which now have better
survival rates due to the development of newer immunologic
and molecularly targeted agents (anti–CTLA-4, anti–PD-1
antibodies, and BRAF inhibitors) [3]. In light of these, the 
molecular targets in the pathogenesis of SMM need to be
clarified as it could ultimately lead to better treatment out-
come. 
Although the precise pathogenetic mechanism in the 
development of SMM is unclear, the malignant transforma-
tion of melanocytes is thought to occur through sequential
accumulation of genetic and molecular alterations. Given
that the alterations in intracellular signaling cascades of
MAPK and PI3K-AKT pathways contribute to the pathogen-
esis of melanoma, genetic aberrations of BRAF/NRAS/
HRAS/KRAS, PIK3CA, c-Kit, and PTEN were examined in
our patient. No mutation, amplification, or deletion of the
candidate genes was found in the patient sample, whereas
hypermethylation of the PTEN promoter was found. 
Sporadic melanomas may have loss of PTEN through loss
of heterozygosity, deletion, or mutation [1]. On the other
hand, epigenetic PTEN silencing without PTENmutation has
also been studied. In one study with 34 melanomas, 61% of
the specimens showed reduced or absent PTEN expression
but neither PTENmutation nor deletion was observed (11 of
18, 61%), suggesting an epigenetic mechanism of biallelic
functional inactivation of PTEN [13]. Another study includ-
ing 37 sera from melanoma patients showed positional
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Fig. 3. Examination of PTEN polymerase chain reaction (PCR) product and methylation status of PTEN promoter gene. (A)
Agarose gel electrophoresis shows loss of PTEN PCR product in the SK-MEL-24 cell line, which is known to have PTEN
deletion, while the patient sample shows a band of PTEN product. (B) Methylation status of the PTEN promoter examined
by pyrosequencing using bisulfite-modified DNA shows methylation of five different CpG island sites in the patient’s 
genomic DNA.
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methylation of CpG islands in the PTEN gene, which leads
to reduced PTEN expression [4]. In cutaneous melanomas, 
a direct relationship between PTEN hypermethylation and
its decreased expression has been demonstrated [14]. Collec-
tively, epigenetic PTEN silencing appears to be a relevant
mechanism that may contribute to the constitutive activation
of the AKT pathway in melanoma tumorigenesis. 
In SMM, a significant portion of specimens (13 of 27,
48.1%) has shown loss of PTEN by immunohistochemistry
[6]. However, compared to other melanomas, epigenetic
PTEN silencing for this particular melanoma subtype has not
been studied before, possibly due to its low incidence. Our
data suggest that the reduced PTEN expression in our SMM
patient was due to the aberrant methylation of PTEN pro-
moter gene. As loss of function mutations in PTEN occur in
only a fraction of PTEN-deficient tumors, PTEN expression
may be lost by various other mechanisms including genomic
deletion, epigenetic and transcriptional silencing. Therefore,
it is necessary to determine PTEN status in tumors by protein
quantification, DNA sequencing and the methylation status
of the CpG islands of PTEN, considering that the mecha-
nisms of epigenetic silencing are increasingly being recog-
nized in melanoma. 
Data on the role of PTEN genes in the process of melanoma
cell transformation and tumor progression are still inconclu-
sive. In cutaneous melanoma, PTEN methylation has been
related to increased mortality [14]. However, in another
study, decreased PTEN expression showed correlation with
ulceration, but not with survival in melanoma patients [15].
Although there are contrasting results, the need to examine
alterations of PTEN and their clinical relevance seems 
increasingly important. 
The ideal treatment of SMM remains obscure and no 
definitive conclusions have been reached. Surgical excision
continues to be the mainstay for treatment of primary SMM.
For poor surgical candidates, targeted therapy, radiotherapy
and chemotherapy can be considered. So far, treatment 
options are limited for patients without BRAF mutations. 
Response rate of chemotherapy including dacarbazine and
other cytotoxic agents is approximately 10% to 20%, irrespec-
tive of the different regimens used [1]. Chemotherapy fails
to prolong survival and is often used as palliative treatment
for those with advanced disease [1]. In our patient, palliative
dacarbazine alone was administered, and partial response
was noted with improved patient’s quality of life. However,
progression of the disease eventually occurred after the sixth
cycle. The 5-year overall survival rate for SMM ranges from
17.1% to 35.1% [1], and is reported to be even lower in 
patients with metastasis [12]. 
To the best of our knowledge this is the first case of SMM
to show decreased PTEN expression due to methylation of
PTEN promoter gene. Our case additionally supports PTEN
as one of the major tumor suppressor involved in melanoma
tumorigenesis and also the possibility of the epigenetic
mechanism of PTEN silencing in development of SMM.
However, it should be emphasized that more case studies 
examining the methylation of PTEN promoter status in SMM
will be needed to support the presumption. Further compar-
ative studies of PTENmethylation status in normal mucosal
tissue, benign sinonasal tumors and SMM should be con-
ducted to determine the precise role of epigenetic PTEN
silencing in SMM.
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